AbbVie Seeks Approval for Pediatric Use of Risankizumab in Psoriasis Treatments
In a significant step towards improving treatments for pediatric psoriasis, AbbVie, a leading biopharmaceutical company, has announced its application for additional approval of Risankizumab for children. This biologic drug is aimed at addressing inadequate responses in existing treatments for various types of psoriasis, including plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis.
Psoriasis is a chronic inflammatory skin disorder characterized by red patches covered with silvery scales. There are approximately 430,000 people suffering from this condition in Japan alone, with children representing a small percentage—0.8% in those aged 0-9 and 1.8% in those aged 10-19. These statistics highlight the urgent need for effective treatment options in the pediatric population, as the current guidelines and therapies available are limited.
The symptoms of psoriasis can lead to significant physical and psychological distress, particularly in children. Observable signs often appear on visible areas of the body such as the scalp and nails, which can elicit a stigmatizing response from peers and adults alike. This might adversely affect the overall quality of life, leading to emotional issues like anxiety and depression. Moreover, pediatric psoriasis is associated with several comorbidities, including obesity, hypertension, and Crohn's disease, exacerbating the situation.
Risankizumab, a selective IL-23 inhibitor, works by binding to the p19 subunit of interleukin-23 to inhibit its action, addressing the underlying inflammatory processes associated with psoriasis. Till now, it has been approved for seven indications in Japan, showcasing promising results in managing chronic immuno-mediated inflammatory conditions.
AbbVie’s application is reportedly based on the results from two major international Phase 3 studies (M19-977 and M19-973), which targeted moderate to severe pediatric plaque psoriasis patients. Such robust clinical trials are essential in demonstrating the efficacy and safety of this treatment in children, paving the way for improved management options.
Currently, the field of pediatric psoriasis treatment lacks comprehensive guidelines, creating a significant unmet need for effective therapeutic alternatives. As pediatric psoriasis often demands prolonged treatment into adult years, new medications like Risankizumab could potentially bridge the treatment gap and provide better health outcomes for young patients.
AbbVie remains committed to tackling pressing health challenges by developing innovative treatments. The company is not only focused on improving the lives of individuals dealing with immune disorders but is also actively involved in research targeting critical healthcare issues across diverse therapeutic areas including immunology, oncology, and neuroscience.
For more information about AbbVie and its initiatives, you can visit their global website or follow their social media channels. The quest for better treatment solutions for psoriasis in pediatric populations is an ongoing journey, and AbbVie is at the forefront of this vital endeavor.
Psoriasis is a chronic inflammatory skin disorder characterized by red patches covered with silvery scales. There are approximately 430,000 people suffering from this condition in Japan alone, with children representing a small percentage—0.8% in those aged 0-9 and 1.8% in those aged 10-19. These statistics highlight the urgent need for effective treatment options in the pediatric population, as the current guidelines and therapies available are limited.
The symptoms of psoriasis can lead to significant physical and psychological distress, particularly in children. Observable signs often appear on visible areas of the body such as the scalp and nails, which can elicit a stigmatizing response from peers and adults alike. This might adversely affect the overall quality of life, leading to emotional issues like anxiety and depression. Moreover, pediatric psoriasis is associated with several comorbidities, including obesity, hypertension, and Crohn's disease, exacerbating the situation.
Risankizumab, a selective IL-23 inhibitor, works by binding to the p19 subunit of interleukin-23 to inhibit its action, addressing the underlying inflammatory processes associated with psoriasis. Till now, it has been approved for seven indications in Japan, showcasing promising results in managing chronic immuno-mediated inflammatory conditions.
AbbVie’s application is reportedly based on the results from two major international Phase 3 studies (M19-977 and M19-973), which targeted moderate to severe pediatric plaque psoriasis patients. Such robust clinical trials are essential in demonstrating the efficacy and safety of this treatment in children, paving the way for improved management options.
Currently, the field of pediatric psoriasis treatment lacks comprehensive guidelines, creating a significant unmet need for effective therapeutic alternatives. As pediatric psoriasis often demands prolonged treatment into adult years, new medications like Risankizumab could potentially bridge the treatment gap and provide better health outcomes for young patients.
AbbVie remains committed to tackling pressing health challenges by developing innovative treatments. The company is not only focused on improving the lives of individuals dealing with immune disorders but is also actively involved in research targeting critical healthcare issues across diverse therapeutic areas including immunology, oncology, and neuroscience.
For more information about AbbVie and its initiatives, you can visit their global website or follow their social media channels. The quest for better treatment solutions for psoriasis in pediatric populations is an ongoing journey, and AbbVie is at the forefront of this vital endeavor.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.